PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

Acta Oncologica

Volumn 53, Issue 6, 2014, Pages 776-787

  Jorgensen, Charlotte L T ^a,b   Nielsen, Torsten O ^c   Bjerre, Karsten D ^b   Liu, Shuzhen ^c   Wallden, Brett ^d   Balslev, Eva ^a   Nielsen, Dorte L ^a   Ejlertsen, Bent ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Danish Breast Cancer Cooperative Group   (Denmark)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NANOSTRING TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; GEMCITABINE; PARAFFIN; RNA; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MESSENGER RNA; TAXOID;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; GENE EXPRESSION ASSAY; HAZARD RATIO; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAM50 INTRINSIC SUBTYPE CLASSIFICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RNA ISOLATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; ADVANCED CANCER; ASSAY; BASAL LIKE BREAST CANCER; BONE METASTASIS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; DISEASE FREE INTERVAL; GENE EXPRESSION; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; PAM50 ASSAY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TAXOIDS;

EID: 84900472653     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.865076     Document Type: Article

References (26)

1. Modi S, Currie VE , Seidman AD , Back AM , Panageas KS , Theodoulou M , et al . A phase II trial of gemcitbaine in patients with metastatic breast cancer previously treated with an anthracycline and taxane . Clin Breast Cancer 2005 ; 6 : 55-60 .
2. Albain KS , Nag SM , Calderillo-Ruiz G , Jordaan JP , Llombart AC , Pluzanska A , et al . Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment . J Clin Oncol 2008 ; 26 : 3950-7 .
3. Chew HK, Doroshow JH, Frankel P , Margolin KA , Somlo G , Lenz H-J , et al . Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer . J Clin Oncol 2009 ; 27 : 2163-9 .
4. Mart?n M , Ruiz A , Mu?oz M , Balil A , Garcia-Mata J, Calvo L , et al . Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial . Lancet Oncol 2007 ; 8 : 219-25 .
5. Hastak K, Alli E, Ford JM . Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin . Cancer Res 2010 ; 70 : 7970-80 .
6. Neve RM , Chin K , Fridlyand J , Yeh J , Baehner FL, Fevr T , et al . A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes . Cancer Cell 2006 ; 10 : 515-27 .
7. S?nchez-Mu?oz A , Due?as-Garcia R , Ja? n-Morago A , Carrasco E , Chac ? n I , Garcia-Tapiador AM , et al . Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination? Results from a phase II trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine trastuzumab in stage II and III breast cancer patients . Am J Clin Oncol 2010 ; 33 : 432-7 .
8. El Saghir NS , Tfayli A , Hatoum HA , Nachef Z, Dinh P , Awada A . Treatment of metastatic breast cancer: State-ofthe- art, subtypes and perspectives . Crit Rev Oncol Hematol 2011 ; 80 : 433-49 .
9. Perou CM , S?rlie T , Eisen MB , van de Rijn M , Jeffrey SS , Rees CA , et al . Molecular portraits of human breast tumours . Nature 2000 ; 406 : 747-52 .
10. S?rlie T , Perou CM , Tibshirani R , Aas T , Geisler S , Johnsen H , et al . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications . Proc Natl Acad Sci U S A 2001 ; 98 : 10869-74 .
11. Galanina N , Bossuyt V , Harris LN . Molecular predictors of response to therapy for breast cancer . Cancer J 2011 ; 17 : 96-103 .
12. Parker SP , Mullins M , Cheang MCU , Leung S , Voduc D , Vickery T , et al . Supervised risk predictor of breast cancer based on intrinsic subtypes . J Clin Oncol 2009 ; 27 : 1160-7 .
13. Nielsen DL , Bjerre KD , Jakobsen EH, Cold S , Stenbygaard L , S?rensen PG , et al . Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: A randomized, phase III study by the Danish Breast Cancer Cooperative Group . J Clin Oncol 2011 ; 29 : 4748-54 .
14. Kennecke H , Yerushalmi R , Woods R , Cheang MCU , Voduc D , Speers CH , et al . Metastatic behavior of breast cancer subtypes . J Clin Oncol 2010 ; 28 : 3271-7 .
15. Geiss G K , Bumgarner RE , Birditt B , Dahl T , Dowidar N , Dunaway DL , et al . Direct multiplexed measurement of gene expression with color-coded probe pairs . Nat Biotechnol 2008 ; 26 : 317-25 .
16. Liu Y , Hayes D , Nobel A , Marron J . Statistical significance of clustering for high-dimensional, low-sample size data . JASA 2008 ; 103 : 1281-93 .
17. Carey L , Perou C . Gene arrays, prognosis, and therapeutic interventions . In: Harris JR , Lippman ME , Morrow M , Osborne CK , editors . Diseases of the breast , 4th ed . Philadelphia: Lippincott Williams & Wilkins ; 2009 . p. 458 - 72 .
18. Dowsett M , Sestak I , Lopez-Knowles E , Sidhu K , Dunbier AK , Cowens JW , et al . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy . J Clin Oncol 2013 ; 31 : 2783-90 .
19. Gnant M , Filipits M , Mlineritsch B, Dubsky P , Jakesz R , Kwasny W , et al . Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distantrecurrence (DR) after endocrine therapy in postmenopausal women with HR early breast cancer (EBC): An ABCSG study . Cancer Res 2012 ; 72(24 Suppl 3) :Abstract P2-10-02.
20. McShane LM , Altman DG , Sauerbrei W , Taube SE , Gion M , Clark GM . REporting recommendations for tumor MARKer prognostic studies (REMARK) . Eur J Cancer 2005 ; 41 : 1690-6 .
21. Simon RM , Paik S , Hayes DF . Use of archived specimens in evaluation of prognostic and predictive biomarkers . J Natl Cancer Inst 2009 ; 101 : 1446-52 .
22. Gonzales-Angulo AM , Iwamoto T , Liu S , Chen H , Do K-A , Hortobagyi GN , et al . Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer . Clin Cancer Res 2012 ; 18 : 1109-19 .
23. Konecny G E , Thomssen C , L?ck HJ, Untch M , Wang H -J, Kuhn W , et al . HER-2/neu gene amplifi cation and response to paclitaxel in patients with metastatic breast cancer . J Natl Cancer Inst 2004 ; 96 : 1141-51 .
24. Van Poznak C, Tan L, Panageas KS , Arroyo CD , Hudis C, Norton L , et al . Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer . J Clin Oncol 2002 ; 20 : 2319-26 .
25. Carey L A . Through a glass darkly: Advances in understanding breast cancer biology, 2000 - 2010 . Clin Breast Cancer 2010 ; 10 : 188-95 .
26. Nielsen T O , Parker JS , Leung S , Voduc D , Ebbert M , Vickery T , et al . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer . Clin Cancer Res 2010 ; 16 : 5222-32 .